secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001493152-25-027529
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma amends CEO Jabbour's employment agreement extending retention bonus window to June 30, 2026
--------------------------------------------------------------------------------

- Retention bonus trigger extended from Mar 31, 2026 to Jun 30, 2026; 2/3 paid upon signing definitive agreement, 1/3 at closing.
- CEO guaranteed 2025 annual bonus at target, payable by Feb 1, 2026, subject to continued employment.
- Change in Control definition expanded to include material change to primary business.
- Cause and Good Reason definitions modified; company confirms no grounds for Cause exist as of Dec 12, 2025.
- Company to reimburse CEO up to $20,000 for legal fees incurred for amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225027529/0001493152-25-027529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225027529/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer